CSIMarket
 
Vaccitech Plc  (VACC)
Other Ticker:  
 
 
Price: $5.0000 $0.51 11.359%
Day's High: $5.1 Week Perf: 19.05 %
Day's Low: $ 4.28 30 Day Perf: 35.5 %
Volume (M): 165 52 Wk High: $ 5.10
Volume (M$): $ 827 52 Wk Avg: $2.51
Open: $4.60 52 Wk Low: $1.64



 Market Capitalization (Millions $) 192
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) 13
 Net Income (TTM) (Millions $) -55
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 12

Vaccitech Plc
Vaccitech Plc is a biopharmaceutical company that specializes in the development of vaccines for various infectious diseases, including viral infections, such as influenza and hepatitis B. The company was founded in 2016 as a spin-out from the University of Oxford's Jenner Institute, and it has since gained recognition for its innovative approach to vaccine development.

Vaccitech's proprietary technology platform, known as the chimpanzee adenovirus vector (ChAdOx) system, enables the delivery of vaccines that stimulate a strong immune response against specific pathogens. This platform has been used in the development of several vaccine candidates, including the COVID-19 vaccine developed in collaboration with AstraZeneca.

In addition to its COVID-19 vaccine, Vaccitech is actively involved in the development of vaccines for other infectious diseases, such as MERS (Middle East Respiratory Syndrome) and human papillomavirus (HPV). The company also collaborates with various partners, including academic institutions, pharmaceutical companies, and government agencies, to advance its vaccine pipeline and bring its products to market.

Vaccitech Plc went public in April 2021 through an initial public offering (IPO) on the Nasdaq stock exchange, raising approximately $168 million. The company continues to focus on advancing its vaccine candidates, expand its pipeline, and contribute to global efforts to combat infectious diseases.


   Company Address: Unit 6-10, Zeus Building Rutherford Avenue Didcot 0
   Company Phone Number: 1865 818 808   Stock Exchange / Ticker: NASDAQ VACC
   VACC is expected to report next financial results on March 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vaccitech Plc

Vaccitech Plc Plunges in Q2 2023 Earnings Season with Astounding -98.043% Revenue Decline

Over the past five trading days, shares of Vaccitech Plc have experienced a decline of -3.52%. This drop contributes to a year-to-date performance decrease of -8.75%. It is important to note that the company's shares are currently trading 8.4% above their 52-week low.
These downward trends may be attributed to the recently announced financial results for the April to June 30, 2023 period. The Major Pharmaceutical Preparations company reported a disastrous performance during this timeframe, with revenue plummeting by a staggering -98.043% to just $0.33 million. Additionally, the company's shortfall per share has widened to $-0.62, compared to the same reporting season from the previous year when it was $-0.48.

Vaccitech Plc

Vaccitech Plc Reports Dismal Q1 2023 Performance, Witnessing a Drastic Decline in Revenue and Higher Losses Compared to Previous Year

Vaccitech Plc, a healthcare company, reported a cumulative net loss of $-15 million in the 12 months ending in the first quarter of 2023, resulting in a negative return on investment of -6.02%. This performance left Vaccitech Plc trailing behind 199 other companies in the healthcare sector that had a higher return on investment.
In the first quarter of 2023, Vaccitech Plc suffered a disastrous period, with revenue plummeting by -96.884% to $0.47 million. The net loss per share increased to $-0.48 from the preceding quarter, resulting in a significant drop in the company's earnings. This decline was further compounded by declining revenue in that period by -92.752% from $6.46 million.






 

Vaccitech Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com